Real-world study backs safety of Hemlibra for acquired hemophilia A
WHY IT MATTERS
If you have acquired hemophilia A in Japan or are considering treatment options, this study suggests Hemlibra may be a safe addition to your treatment plan, though you should discuss this with your hematologist to see if it's right for your specific situation.
A study in Japan found that Hemlibra, a medicine used to treat acquired hemophilia A (a rare bleeding disorder that develops later in life), appears to be safe when used alongside other medications that suppress the immune system. Acquired hemophilia A is different from the hemophilia people are born with—it happens when the body mistakenly attacks its own clotting proteins. This is the first real-world evidence supporting Hemlibra's safety for this condition in actual patients.
Hemlibra (emicizumab) alongside immunosuppressive therapy appears safe for use in acquired hemophilia A (AHA), according to initial results of a real-world study in Japan, the only country where Hemlibra has approval for this indication. “At this interim analysis, there were no unexpected safety concerns for … patients with AHA treated with [Hemlibra], and the consistently […] The post Real-world study backs safety of Hemlibra for acquired hemophilia A appeared first on Hemophilia Ne
ASK YOUR DOCTOR
If you have acquired hemophilia A, ask your doctor whether Hemlibra combined with immunosuppressive therapy might be appropriate for your treatment, especially if you live in Japan or have access to this medication.